- Home
- RIGL vs REFI Comparison
RIGL vs REFI Comparison
Compare RIGL & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- REFI
- Stock Information
- Founded
- RIGL 1996
- REFI 2021
- Country
- RIGL United States
- REFI United States
- Employees
- RIGL N/A
- REFI N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- RIGL Health Care
- REFI Real Estate
- Exchange
- RIGL Nasdaq
- REFI Nasdaq
- Market Cap
- RIGL 335.5M
- REFI 283.7M
- IPO Year
- RIGL 2000
- REFI 2021
- Fundamental
- Price
- RIGL $30.17
- REFI $12.62
- Analyst Decision
- RIGL Buy
- REFI Strong Buy
- Analyst Count
- RIGL 5
- REFI 3
- Target Price
- RIGL $38.20
- REFI $20.00
- AVG Volume (30 Days)
- RIGL 668.8K
- REFI 184.7K
- Earning Date
- RIGL 11-06-2025
- REFI 11-06-2025
- Dividend Yield
- RIGL N/A
- REFI 16.28%
- EPS Growth
- RIGL N/A
- REFI N/A
- EPS
- RIGL 5.43
- REFI 1.84
- Revenue
- RIGL $267,921,000.00
- REFI $56,608,781.00
- Revenue This Year
- RIGL $59.93
- REFI $11.43
- Revenue Next Year
- RIGL N/A
- REFI $4.75
- P/E Ratio
- RIGL $5.32
- REFI $6.89
- Revenue Growth
- RIGL 105.62
- REFI 2.58
- 52 Week Low
- RIGL $13.57
- REFI $12.33
- 52 Week High
- RIGL $43.72
- REFI $16.29
- Technical
- Relative Strength Index (RSI)
- RIGL 39.94
- REFI 33.73
- Support Level
- RIGL $27.75
- REFI $12.33
- Resistance Level
- RIGL $29.46
- REFI $12.97
- Average True Range (ATR)
- RIGL 1.49
- REFI 0.28
- MACD
- RIGL -0.41
- REFI -0.06
- Stochastic Oscillator
- RIGL 25.90
- REFI 21.58
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.